SD BIOSENSOR INC.
Financials
Valuation Metrics
SD BIOSENSOR INC.'s Market Cap is ₩7764B. At end of 2025 it was ₩1.1T. Ranked #332 of 2,410 in KR market (top 14%), #237 of 779 on KOSPI (top 30%), #8 of 94 in Health Care Equipment & Services (top 9%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 776.42B KRW | KR#332/2,410 Sec#8/94 |
| Revenue | 738.76B KRW | KR#491/2,410 Sec#4/94 |
| Net Income | -731.09B KRW | KR—/2,410 Sec—/94 |
| Total Assets | 2.90T KRW | KR#245/2,410 Sec#1/94 |
| Net Assets | 2.41T KRW | KR#159/2,410 Sec#1/94 |
| Employees | 613 | KR#407/2,410 Sec#6/94 |
| Value | ||
| P/B | 0.32x | KR#454/2,410 Sec#6/94 |
| P/S | 1.05x | KR#1,468/2,410 Sec#31/94 |
| FCF Yield | 38.69% | KR#146/2,410 Sec#2/94 |
| Profitability | ||
| ROE | -30.39% | KR#2,176/2,410 Sec#78/94 |
| ROA | -25.20% | KR#2,273/2,410 Sec#84/94 |
| Op. Margin | -8.75% | KR#1,958/2,410 Sec#62/94 |
| Revenue Growth | 5.15% | KR#1,183/2,410 Sec#63/94 |
| Earnings Growth | -489.33% | KR#1,297/2,410 Sec#46/94 |
| Financial Health | ||
| Debt Ratio | 20.61% | KR#379/2,410 Sec#21/94 |
| Total Debt | 536.85B KRW | KR#292/2,410 Sec#2/94 |
| FCF | 300.43B KRW | KR#88/2,410 Sec#1/94 |
| Cash | 230.22B KRW | KR#235/2,410 Sec#2/94 |
| Current Ratio | 6.51x | KR#188/2,410 Sec#17/94 |
| Dividend | ||
| Div. Yield | 3.16% | KR#653/2,410 Sec#11/94 |
| Div. Growth | 0.00% | KR—/2,410 Sec—/94 |
| Performance | ||
| 1Y Return | -32.67% | KR#1,569/2,410 Sec#49/94 |
| 1M Return | 1.42% | KR#225/2,410 Sec#7/94 |
| From 52W High | -36.90% | KR#664/2,410 Sec#21/94 |
| 1Y MDD | -42.26% | KR#648/2,410 Sec#22/94 |
| Trading | ||
| Volume | 72,269 shares | KR#813/2,410 Sec#30/94 |
| Trading Value | 462.6M KRW | KR#871/2,410 Sec#27/94 |
| Foreign Own. | 5.97% | KR#732/2,410 Sec#22/94 |
| Per Share | ||
| EPS | -6,055 KRW | KR—/2,410 Sec—/94 |
| BPS | 19,924 KRW | KR#536/2,410 Sec#6/94 |
Company Info
SD BIOSENSOR, established in 2010 as a spin-off from SD Co., Ltd.'s biosensor division, is a mid-sized company as of 2024. The company primarily focuses on R&D and sales of in-vitro diagnostics, including immunochemistry, molecular, point-of-care, and self-blood glucose monitoring. SD BIOSENSOR is expanding its global market and portfolio through a network of over 100 exclusive dealers, direct sales in key countries, and quality competitiveness, including WHO PQ approval. Headquartered in Suwon, Gyeonggi-do, it was founded in 2010.